Zum Hauptinhalt springen
xMedica

NCT06956014ClinicalTrials.gov

Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy

Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of the Full-spectrum Cannabis Extract VER-01 in Participants With Chronic Painful Lumbosacral Radiculopathy

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The aim of the trial is to prove the efficacy and safety of VER-01 compared to placebo in patients with chronic painful lumbosacral radiculopathy (PLSR) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not…

Phase 3810 Teilnehmende gesucht43 Studienzentren1 Land

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2025-05-02; recorded start 2026-09-22
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (Vertanical GmbH)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 810 participants (target), run at 43 sites.

How this score is built
  • Enrolment29/40

    810 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale1/10

    Vertanical GmbH has led 3 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The aim of the trial is to prove the efficacy and safety of VER-01 compared to placebo in patients with chronic painful lumbosacral radiculopathy (PLSR) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Erkrankungen

  • Lumbosacral Radiculopathy

Eignung

Eignung
GeschlechtAlle
Alter18 Years – Kein Höchstalter
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Inclusion Criteria: * Participants ≥ 18 years of age, all sexes * Participant voluntarily provided written informed consent * Participant is willing and able to comply with scheduled visits, treatment plan, eDiary, and other trial-related procedures throughout trial participation Exclusion Criteria: * Pregnant or breastfeeding female patients * Known history of previous or current severe psychiatric disorder as per DSM-5 (e.g., schizophrenia, bipolar disorder, severe anxiety disorder, psychotic disorder, post-traumatic stress disorder), or currently taking antipsychotic medication * Cardiovascular event or clinically significant cardiac dysfunction (e.g., congestive heart failure, myocardial ischemia, arrhythmias, poorly controlled high blood pressure, congenital long QT syndrome) within 12 months or a cardiac disorder that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypInterventionell
PhasePhase 3
ZuteilungRandomisiert
InterventionsmodellPARALLEL
Primäres ZielTREATMENT
VerblindungQUADRUPLE (4)
Teilnahme810 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Vertanical GmbH Sponsor

Studienarme und Interventionen

  • VER-01 Dose 1EXPERIMENTAL
  • VER-01 Dose 2EXPERIMENTAL
  • PlaceboPLACEBO_COMPARATOR

Interventionen

  • Sonstige Placebo

    Comparator without active ingredient

  • Arzneimittel VER-01

    Standardized soft extract from Cannabis sativa DKJ127 L., cannabis flos (Cannabis flower), corresponding to 19 mg Δ9-Tetrahydrocannabinol (THC) per ml drug product

Endpunkte

  1. Primärer Endpunkt

    Efficacy based on pain reduction

    The primary endpoint is the absolute change in mean leg pain intensity in the index leg measured on an 11-point numerical rating scale (NRS) at Treatment Week 12 compared to Baseline.

    Zeitrahmen From Baseline to Treatment Week 12

Daten

Daten
Startdatum22. September 2026 (tatsächlich)
Primärer Abschluss1. September 2028 (geschätzt)
Abschluss1. September 2028 (geschätzt)
Erstveröffentlichung2. Mai 2025 (tatsächlich)
Zuletzt aktualisiert19. November 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtNovember 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

43 Studienzentren rekrutieren

United States

United States
EinrichtungStadtBundesland oder RegionStatus
Central Texas Clinical Research, LLCAustinTexasRekrutiert
Boston Clinical TrialsBostonMassachusettsRekrutiert
Bradenton Research CenterBradentonFloridaRekrutiert
DFW Clinical TrialsCarrolltonTexasRekrutiert
Epic Medical Research - CarroltonCarrolltonTexasRekrutiert
Clinitiative - Clinical Trials of South Carolina - CharlestonCharlestonSouth CarolinaRekrutiert
Epic Medical Research - ChickashaChickashaOklahomaRekrutiert
Velocity Clinical Research - ClevelandClevelandOhioRekrutiert
Epic Medical Research - DeSotoDeSotoTexasRekrutiert
Mountain View Clinical ResearchDenverColoradoRekrutiert
Innovare Research Group IFriendswoodTexasRekrutiert
AGA Clinical TrialsHialeahFloridaRekrutiert
HD Research - Memorial Hermann VillageHoustonTexasRekrutiert
Perfizien Clinical Research LLCHoustonTexasRekrutiert
Synergy Groups Medical - Southeast HoustonHoustonTexasRekrutiert
Green Leaf Clinical TrialsJacksonvilleFloridaRekrutiert
R & H Clinical ResearchKatyTexasRekrutiert
Alliance for Multispecialty Research - KnoxvilleKnoxvilleTennesseeRekrutiert
Epic Clinical Research - LewisvilleLewisvilleTexasRekrutiert
Central Medical Research InstituteLong BeachCaliforniaRekrutiert
Tekton Research - LongmontLongmontColoradoRekrutiert
K2 Medical Research - Maitland IIMaitlandFloridaRekrutiert
Velocity Clinical Research - MedfordMedfordOregonRekrutiert
Alma Clinical ResearchMiamiFloridaRekrutiert
Floridian Research Institute LLC IMiamiFloridaRekrutiert
AMR MobileMobileAlabamaRekrutiert
Monroe Biomedical Research - MonroeMonroeNorth CarolinaRekrutiert
Alliance for Multispecialty Research - NorfolkNorfolkVirginiaRekrutiert
Conquest Research - Lake NonaOrlandoFloridaRekrutiert
Alfa Medical Research - Pembroke PinesPembroke PinesFloridaRekrutiert
Flourish Research - PhiladelphiaPlymouth MeetingPennsylvaniaRekrutiert
United Medical ResearchPort OrangeFloridaRekrutiert
Boeson ResearchProvoUtahRekrutiert
CenExel JBR - Salt Lake CitySalt Lake CityUtahRekrutiert
Elixia Clinical Research CollaborativeSpringfieldMassachusettsRekrutiert
Professional Health Care of PinellasSt. PetersburgFloridaRekrutiert
Velocity Clinical Research - SuffolkSuffolkVirginiaRekrutiert
Alliance for Multispecialty Research - Tempe ITempeArizonaRekrutiert
Alliance for Multispecialty Research - Wichita EastWichitaKansasRekrutiert
Grayline Research CenterWichita FallsTexasRekrutiert
Progressive Medicine of the Triad, LLCWinston-SalemNorth CarolinaRekrutiert
Conquest Research - Winter ParkWinter ParkFloridaRekrutiert
Vitalix ClinicalWorcesterMassachusettsRekrutiert

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 19. November 2026

    Studienzentrum hinzugefügt

    11 sites added (43 total)

    3243

  2. 2. November 2026

    Studienzentrum hinzugefügt

    9 sites added (32 total)

    2332

  3. 21. Oktober 2026

    Studienzentrum hinzugefügt

    1 site added (23 total)

    2223

  4. 19. Oktober 2026

    Studienzentrum hinzugefügt

    21 sites added (22 total)

    122

  5. 28. September 2026

    Status geändert

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  6. 28. September 2026

    Studienzentrum hinzugefügt

    1 site added (1 total)

    01

  7. 28. September 2026

    Rekrutierung eröffnet

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING